Skip to content

艾尔沃科技

US · ALVO #2709 按市值排名 上市于 2020
5.00 -0.31 -5.84%
实时 - 追踪5344个代码 - 心跳于246秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 -10.85 低于历史水平 第10百分位
5年平均 -6.15
市盈率 -10.07 低于历史水平 第15百分位
5年平均 1.18 · 前瞻 31.42
市销率 4.45 处于历史正常水平 第34百分位
5年平均 18.45 · 前瞻 2.76 · 在Drug Manufacturers - Specialty & Generic中排名第58/80

同业对比 Drug Manufacturers - Specialty & Generic

公司 市值 市盈率(TTM) 市净率 股息率
艾尔沃科技 (ALVO) 1.78B -8.20 -8.83 0.00%
Takeda Pharmaceutical (TAK) 62.84B -59.43 1.31 3.04%
Teva Pharmaceutical Industries (TEVA) 48.40B 69.17 6.24 0.00%
Haleon (HLN) 44.55B 21.06 2.05 1.88%
Zoetis (ZTS) 32.80B 12.95 10.42 2.60%
United Therapeutics (UTHR) 22.87B 19.10 3.57 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值8.89 经济护城河None 不确定性High

当前股价低于晨星合理价值估算77.7%。

合理价值

While Alvotech may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 31% discount to our quantitative fair value estimate of $8.89 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet strengthens our valuation estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's debt to EBITDA ratio of 9.3 lies in the top 20% globally. The firm has a high level of debt relative to its asset base, which can signal significant investment in the business or a pending merger. In either case, it may suggest future growth in cash flows. We believe this is a sign that shares could be cheap.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 25.0, a core component of valuation, falls in the top 30% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

经济护城河

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

艾尔沃科技 讨论区 0 条评论

发表评论